…ING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – Two analyses of data from the phase III FREEDOMS trial report that fingolimod increases the proportion of MS patients who are disease-free and reduces brain atrophy compared to placebo. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

…rferon-1a (CAMMS223 Trial Investigators et al. N Engl J Med 2008; 359: 1786-1801; free full text at www.nejm.org/doi/full/10.1056/NEJMoa0802670). Alemtuzumab dosing groups received either 12 or 24 mg IV x 1 cycle/year. While alemtuzumab appeared to be more effective than beta-interferon (annualized relapse rate 0.10 vs. 0.36), alemtuzumab was suspended after three patients developed immune thrombocytopenia purpura (ITP). Subscribe to read more It…

…ETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – A retrospective analysis of patients who discontinued natalizumab has concluded that there is an elevated risk of increased disease activity and worsening disability if the drug is stopped (Kelly et al. AAN 2011; abstract P01.197). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the…

…MY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – An analysis of data from the phase III FREEDOMS trial of fingolimod in relapsing-remitting MS reports that 3-month disability progression is reduced by about one-third overall, with reductions seen consistently across all predefined subgroups (Devonshire et al. AAN 2011; abstract P01.198). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email…